Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in advanced non-squamous NSCLC
NCT02590965Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- May 2014
- Primary completion
- Aug 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Hutchison MediPharma (HMP). Started May 2014; status: completed.
02
Drugs
fruquintinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT02590965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590965.